Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €53.91 EUR
Change Today +0.14 / 0.26%
Volume 15.0
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 5:36 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
€53.91
Previous Close
€53.77
Day High
€53.91
Day Low
€53.91
52 Week High
01/26/15 - €56.20
52 Week Low
08/8/14 - €39.00
Market Cap
152.3B
Average Volume 10 Days
275.4
EPS TTM
--
Shares Outstanding
2.8B
EX-Date
03/16/15
P/E TM
--
Dividend
€1.85
Dividend Yield
2.70%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, including antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

70,000 Employees
Last Reported Date: 02/27/15
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $3.2M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.5M
President of Global Human Health and Executiv...
Total Annual Compensation: $962.4K
Executive Vice President and General Counsel
Total Annual Compensation: $807.5K
Compensation as of Fiscal Year 2014.

merck & co. inc. (MRK) Key Developments

Merck Receives FDA Fast Track Designation for Evofosfamide for Treatment of Patients Living with Advanced Pancreatic Cancer

Merck announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. Evofosfamide is an investigational hypoxia-activated prodrug thought to be activated under severe tumor hypoxic conditions, a feature of many solid tumors. The compound, currently in Phase III trials, is being developed in collaboration with Threshold Pharmaceuticals Inc.

Merck & Co. Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM

Merck & Co. Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States.

Plexxikon Inc. and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

Plexxikon Inc. and Merck announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikon’s investigational CSF-1R inhibitor, and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression. The Phase 1/2 trial will enroll patients with advanced melanoma and multiple other solid tumors with the goal of determining the safety and tolerability of the combination therapy. The trial is expected to begin enrollment by mid-year. PLX3397 is a novel oral small molecule that potently and selectively inhibits CSF-1R, KIT, and mutant FLT3 kinases. CSF1R and KIT regulate key components of both the tumor and its microenvironment (macrophages, osteoclasts, mast cells). In addition to melanoma and other solid tumors to be studied in this collaborative trial, PLX3397 is being evaluated in several other clinical indications, including tenosynovial giant cell tumor (TGCT), historically called pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), breast cancer and glioblastoma. KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. KEYTRUDA is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:FP €53.91 EUR +0.14

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $160.98 USD -1.08
Gilead Sciences Inc $111.71 USD +0.49
GlaxoSmithKline PLC 1,444 GBp -20.50
L'Oreal SA €174.60 EUR +0.40
Pfizer Inc $34.28 USD -0.08
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 15.4x
Price/Sales 4.1x
Price/Book 3.5x
Price/Cash Flow 15.0x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.